Claims
- 1. A method of increasing the intraocular amount of a biological agent, comprising providing to an eye of an animal at least a first biological agent and an amount of at least a first prostanoid effective to increase the intraocular amount of said at least a first biological agent.
- 2-105. (canceled)
- 106. The method of claim 1, wherein at least one of said at least a first biological agent and said at least a first prostanoid are provided to said eye by topical administration.
- 107. The method of claim 1, wherein at least one of said at least a first biological agent and said at least a first prostanoid are provided to said eye by subconjunctival injection.
- 108. The method of claim 1, wherein said at least a first biological agent and said at least a first prostanoid are comprised within a single composition.
- 109. The method of claim 1, wherein said at least a first biological agent and said at least a first prostanoid are comprised within distinct first and second compositions.
- 110. The method of claim 109, wherein at least a first composition comprising said at least a first prostanoid is provided to said eye at a biologically effective time prior to at least a second composition comprising said at least a first biological agent.
- 111. The method of claim 109, wherein the composition comprising said at least a first prostanoid is provided to said eye by topical administration and wherein the composition comprising said at least a first biological agent is subsequently provided to said eye by subconjunctival injection.
- 112. The method of claim 1, wherein the intraocular amount of said at least a first biological agent is increased in the aqueous of said eye.
- 113. The method of claim 1, wherein the intraocular amount of said at least a first biological agent is increased in the vitreous of said eye.
- 114. The method of claim 1, wherein at least a second biological agent is further provided to said eye.
- 115. The method of claim 1, wherein at least a second prostanoid is further provided to said eye.
- 116. The method of claim 1, wherein said at least a first prostanoid is a prostaglandin.
- 117. The method of claim 116, wherein said at least a first prostanoid is a PGD or PGF prostaglandin or derivative thereof.
- 118. The method of claim 117, wherein said at least a first prostanoid is a phenyl-substituted, 3-oxa or 3-carba analog of a PGD or PGF prostaglandin.
- 119. The method of claim 117, wherein said at least a first prostanoid is a PGD2 or PGF2α analogue.
- 120. The method of claim 119, wherein said at least a first prostanoid is Latanoprost™.
- 121. The method of claim 1, wherein said at least a first biological agent is a detectable or diagnostic agent.
- 122. The method of claim 1, wherein said at least a first biological agent is a therapeutic agent.
- 123. The method of claim 122, wherein said at least a first biological agent is dilating agent, a mydriatic, a cycloplegic, a miotic or a cholinesterase inhibitor.
- 124. The method of claim 122, wherein said at least a first biological agent is an agent selected from the group consisting of phenylephrine, tropicamide, cyclopentolate, homatropine, scopolamine and atropine.
- 125. The method of claim 122, wherein said at least a first biological agent is a steroid, a non-steroidal anti-inflammatory agent, anti-histamine, anti-glaucoma agent, topical carbonic anhydrase inhibitor, cholinesterase inhibitor, topical beta adrenergic blocking agent, topical alpha adrenergic agonist, reducing agent, anti-oxidant, vitamin, mineral, growth factor, immune modulator, cytokine, hormone, antibody, anesthetic, anti-neoplastic agent.
- 126. The method of claim 122, wherein said at least a first biological agent is an anti-microbial, anti-bacterial, anti-viral, anti-retroviral, anti-parasitic or an anti-fungal agent.
- 127. The method of claim 126, wherein said at least a first biological agent is an anti-microbial agent selected from the group consisting of neomycin, polymyxin B, erythromycin, trimethoprim, sulfacetamide sodium, tetracycline, oxytetracycline, norfloxacin, ciloxan, ciprofloxacin, levafloxacin, ofloxacin, gentamycin, tobramycin, vancomycin, bacitracin, cephazolin, amikacin, ketoconazole, trifluridine, caspofungin, amphotericin B and natamycin.
- 128. The method of claim 126, wherein said at least a first biological agent is a glycopolypeptide, a macrolide, a beta lactam, an aminoglycoside or a quinolone anti-bacterial agent.
- 129. The method of claim 126, wherein said at least a first biological agent is the anti-viral agent ganciclovir, acyclovir, famciclovir, foscarnet or cidofovir.
- 130. The method of claim 126, wherein said at least a first biological agent is the anti-fungal agent voriconazole.
- 131. The method of claim 122, wherein said at least a first biological agent is a protein, polypeptide or peptide.
- 132. The method of claim 122, wherein said at least a first biological agent is DNA, RNA, an antisense construct, a ribozyme, or a plasmid or viral expression vector or recombinant virus containing such a virus.
- 133. The method of claim 1, wherein said at least a first prostanoid is Latanoprost™ and wherein said at least a first biological agent is voriconazole.
- 134. The method of claim 1, wherein said animal has or is suspected of having an allergy or allergies affecting the eye, diabetes, glaucoma, ocular neovascular disease, retinal degeneration, macular degeneration or a vitamin deficiency that affects the eye.
- 135. The method of claim 1, wherein said animal has or is suspected of having an optic neuropathy, a blunt or penetrating ocular injury or an orbital or intraocular tumor.
- 136. The method of claim 1, wherein said animal has or is suspected of having a microbial, bacterial, viral, retroviral, parasitic, fungal or amoebal infection.
- 137. The method of claim 136, wherein said animal has or is suspected of having an acute infection, chronic infection, preseptal cellulitis, orbital cellulitis or periorbital cellulitis.
- 138. The method of claim 136, wherein said animal has or is suspected of having an HIV-, CMV- or HSV-associated retinal disorder, a gram positive bacterial infection, a gram negative bacterial infection, candidiasis, aspergillosis, bacterial or fungal keratitis or endophthalmitis, uveitis, conjunctivitis or an intraocular or periocular inflammation.
- 139. The method of claim 1, wherein said animal has or is preparing to undergo eye surgery.
- 140. The method of claim 139, wherein said animal is preparing to undergo eye surgery and wherein said at least a first biological agent is an anesthetic.
- 141. The method of claim 139, wherein said animal has been subjected to eye surgery and wherein said at least a first biological agent is an anti-microbial, anti-bacterial, anti-viral, anti-retroviral, anti-parasitic or an anti-fungal agent.
- 142. The method of claim 1, wherein said animal is a human subject.
- 143. A method of increasing the amount of voriconazole in the intraocular space of the eye, comprising contacting an eye of an animal with a combined effective amount of voriconazole and Latanoprost™; wherein said Latanoprost™ increases the amount of voriconazole in the intraocular space of said eye in comparison to the amount of voriconazole in the intraocular space of said eye in the absence of said Latanoprost™.
- 144. An ophthalmically acceptable formulation comprising an ocular-transport effective amount of at least a first prostanoid and a therapeutically effective amount of at least a first ophthalmically active biological agent.
- 145. A kit comprising, in at least a first suitable container, a therapeutically effective combination of at least a first prostanoid and at least a first ophthalmically active biological agent.
Parent Case Info
[0001] The present application claims priority to U.S. provisional application Serial No. 60/285,856, filed Apr. 23, 2001, the entire text, figures and claims of which application are incorporated herein by reference without disclaimer.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US02/13057 |
4/23/2002 |
WO |
|
Provisional Applications (1)
|
Number |
Date |
Country |
|
60285856 |
Apr 2001 |
US |